Scholarlink

<p>Colorectal cancer (CRC) treatment remains challenging due to genetic heterogeneity and resistance mechanisms. To address this, we developed a drug discovery pipeline using patient-derived primary CRC cultures with diverse genomic profiles. These cultures closely resemble certain molecular characteristics of primary and metastatic CRC, highlighting their promise as a translational platform for therapeutic evaluation. Importantly, our engineered model and patient-derived cells reflect the complexity and heterogeneity of primary tumors, not observed with standard immortalized cell lines, offering a more clinically relevant system, although further validation is needed. High-throughput screening (HTS) of 4255 compounds identified 33 with selective efficacy against CRC cells, sparing normal, healthy epithelial cells. Among the tested combinations, everolimus (mTOR inhibitor) and uprosertib (AKT inhibitor) demonstrated promising synergy at clinically relevant concentrations, with favorable therapeutic windows confirmed across tested patient-derived cultures. Notably, this synergy, revealed through advanced models, might have been overlooked in traditional immortalized cell lines, highlighting the translational advantage of patient-derived systems. Furthermore, the integration of machine learning into the HTS pipeline significantly improved scalability, cost-efficiency, and predictive accuracy. Our findings underscore the potential of patient-derived materials combined with machine learning-enhanced drug discovery to advance personalized therapies. Specifically, mTOR-AKT inhibition emerges as a promising strategy for CRC treatment, paving the way for more effective and targeted therapeutic approaches.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Integrated transcriptomic and functional modeling reveals AKT and mTOR synergy in colorectal cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月31日

查看全文
  • Marcin Duleba,
  • Eliza Zimoląg,
  • Joanna Szuszkiewicz,
  • Marcin Serocki,
  • Joanna Szklarczyk,
  • Olga Dracz,
  • Alexander Kurzejamski,
  • Izabella Więckowska,
  • Marcelina Chmiel,
  • Barbara Lipert,
  • Katarzyna Sarad,
  • Joanna Krawczyk,
  • Oleksii Bryzghalov,
  • Agata Stachowicz-Wałaszek,
  • Karolina Pyziak,
  • Joanna Drozdowska,
  • Krzysztof Baczyński,
  • Konrad Wojtowicz,
  • Maurycy Chronowski,
  • Krzysztof Rataj,
  • Magdalena Otrocka,
  • Michał Mikula,
  • Paula Feliksiak,
  • Rafał Dziadziuszko,
  • Tomasz Rzymski,
  • Andrew Thomason,
  • Krzysztof Brzózka,
  • Andrzej Mazan

摘要

Colorectal cancer (CRC) treatment remains challenging due to genetic heterogeneity and resistance mechanisms. To address this, we developed a drug discovery pipeline using patient-derived primary CRC cultures with diverse genomic profiles. These cultures closely resemble certain molecular characteristics of primary and metastatic CRC, highlighting their promise as a translational platform for therapeutic evaluation. Importantly, our engineered model and patient-derived cells reflect the complexity and heterogeneity of primary tumors, not observed with standard immortalized cell lines, offering a more clinically relevant system, although further validation is needed. High-throughput screening (HTS) of 4255 compounds identified 33 with selective efficacy against CRC cells, sparing normal, healthy epithelial cells. Among the tested combinations, everolimus (mTOR inhibitor) and uprosertib (AKT inhibitor) demonstrated promising synergy at clinically relevant concentrations, with favorable therapeutic windows confirmed across tested patient-derived cultures. Notably, this synergy, revealed through advanced models, might have been overlooked in traditional immortalized cell lines, highlighting the translational advantage of patient-derived systems. Furthermore, the integration of machine learning into the HTS pipeline significantly improved scalability, cost-efficiency, and predictive accuracy. Our findings underscore the potential of patient-derived materials combined with machine learning-enhanced drug discovery to advance personalized therapies. Specifically, mTOR-AKT inhibition emerges as a promising strategy for CRC treatment, paving the way for more effective and targeted therapeutic approaches.